Brief: Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic Dermatitis

Aldeyra Therapeutics

19/12/2023 13:24

Dec 19 (Reuters) - Aldeyra Therapeutics Inc  ALDX.O :
    * ALDEYRA THERAPEUTICS ANNOUNCES STATISTICALLY AND
CLINICALLY
SIGNIFICANT IMPROVEMENT FROM BASELINE IN PHASE 2 CLINICAL TRIAL
OF ADX-629 IN PATIENTS WITH ATOPIC DERMATITIS
    * ALDEYRA THERAPEUTICS:TRIAL DEMONSTRATED STATISTICALLY
SIGNIFICANT, CLINICALLY RELEVANT IMPROVEMENT IN
INVESTIGATOR-ASSESSED,PATIENT-REPORTED OUTCOMES
    * ALDEYRA THERAPEUTICS INC - EXPECTS TO INITIATE A
MULTICENTER,
RANDOMIZED, PLACEBO-CONTROLLED PHASE 1/2 CLINICAL TRIAL OF
ADX-246 IN FIRST HALF OF 2024
    * ALDEYRA THERAPEUTICS INC - TWO ADVERSE EVENTS DEEMED TO BE
AT
LEAST POSSIBLY RELATED TO ADX-629 WERE REPORTED, AND BOTH EVENTS
WERE MILD

Source text for Eikon:  ID:nBw5rJVCBa 
Further company coverage:  ALDX.O 

 ((Reuters.Briefs@thomsonreuters.com;))